Reports - PipelineReview.com

comparisonsneezeBiotechnology

Dec 1, 2012 (4 years and 11 months ago)

330 views


PipelineReview.com is powered by La Merie Business Intelligence

La Merie S.L | C/Casp 33 B, 4º 2ª | E-08010 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 |
Email info@lamerie.com
| Internet www.lamerie.com


Online Store: www.pipelinereview.com

Reports






France: Pharmaceuticals Industry Guide

Table of Contents

BIOTECHNOLOGY IN FRANCE 7

Market Overview 7
Market Value 9
Market Segmentation I 10
Market Segmentation II 11
Five Forces Analysis 12
Market Forecasts 19

GENERICS IN FRANCE 21

Market Overview 21
Market Value 23
Market Volume 24
Market Segmentation II 25
Five Forces Analysis 26
Market Forecasts 34

OTC PHARMACEUTICALS IN FRANCE 37

Market Overview 37
Market Value 39
Market Segmentation I 40
Market Segmentation II 41
Market Share 42
Five Forces Analysis 43
Market Distribution 51
Market Forecasts 52

PHARMACEUTICALS IN FRANCE 54

Market Overview 54
Market Value 56
Market Segmentation I 57
Market Segmentation II 58
Market Share 59
Five Forces Analysis 60
Market Forecasts 69






PipelineReview.com is powered by La Merie Business Intelligence

La Merie S.L | C/Casp 33 B, 4º 2ª | E-08010 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 |
Email info@lamerie.com
| Internet www.lamerie.com


Online Store: www.pipelinereview.com

Reports



MACROECONOMIC INDICATORS 71
APPENDIX 73

Data Research Methodology 73
About Datamonitor 74
Disclaimer 74

LIST OF TABLES

Table 1: France biotechnology market value: $ billion, 2005–09 9
Table 2: France biotechnology market segmentation I:% share, by value, 2009 10
Table 3: France biotechnology Market Segmentation II: % share, by value, 2009 11
Table 4: France biotechnology market value forecast: $ billion, 2009–14 19
Table 5: France generics market value: $ billion, 2005–09 23
Table 6: France generics market volume: volume penetration, 2005–09 24
Table 7: France generics Market Segmentation II: % share, by value, 2009 25
Table 8: France generics market value forecast: $ billion, 2009–14 34
Table 9: France generics market volume forecast: volume penetration, 2009–14 35
Table 10: France OTC pharmaceuticals market value: $ million, 2005–09 39
Table 11: France OTC pharmaceuticals market segmentation I:% share, by value,
2009 40
Table 12: France OTC pharmaceuticals Market Segmentation II: % share, by value,
2009 41
Table 13: France OTC pharmaceuticals market share: % share, by value, 2009 42
Table 14: France OTC pharmaceuticals market distribution: % share, by value,
2009 51
Table 15: France OTC pharmaceuticals market value forecast: $ million, 2009–14
52
Table 16: France pharmaceuticals market value: $ billion, 2006–10(e) 56
Table 17: France pharmaceuticals market segmentation I:% share, by value,
2010(e) 57
Table 18: France pharmaceuticals Market Segmentation II: % share, by value,
2010(e) 58
Table 19: France pharmaceuticals market share: % share, by value, 2010(e) 59
Table 20: France pharmaceuticals market value forecast: $ billion, 2010–15 69
Table 21: France size of population (million), 2006–10 71
Table 22: France GDP (constant 2000 prices, $ billion), 2006–10 71
Table 23: France GDP (current prices, $ billion), 2006–10 71
Table 24: France inflation, 2006–10 72
Table 25: France consumer price index (absolute), 2006–10 72
Table 26: France exchange rate, 2006–10 72


LIST OF FIGURES

Figure 1: France biotechnology market value: $ billion, 2005–09 9
Figure 2: France biotechnology market segmentation I:% share, by value, 2009 10
Figure 3: France biotechnology Market Segmentation II: % share, by value, 2009
11
Figure 4: Forces driving competition in the biotechnology market in France, 2009
12


PipelineReview.com is powered by La Merie Business Intelligence

La Merie S.L | C/Casp 33 B, 4º 2ª | E-08010 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 |
Email info@lamerie.com
| Internet www.lamerie.com


Online Store: www.pipelinereview.com

Reports



Figure 5: Drivers of buyer power in the biotechnology market in France, 2009 13
Figure 6: Drivers of supplier power in the biotechnology market in France, 2009 14
Figure 7: Factors influencing the likelihood of new entrants in the biotechnology
market in France, 2009 15
Figure 8: Factors influencing the threat of substitutes in the biotechnology market
in France, 2009 17
Figure 9: Drivers of degree of rivalry in the biotechnology market in France, 2009
18
Figure 10: France biotechnology market value forecast: $ billion, 2009–14 20
Figure 11: France generics market value: $ billion, 2005–09 23
Figure 12: France generics market volume: volume penetration, 2005–09 24
Figure 13: France generics Market Segmentation II: % share, by value, 2009 25
Figure 14: Forces driving competition in the generics market in France, 2009 26
Figure 15: Drivers of buyer power in the generics market in France, 2009 28
Figure 16: Drivers of supplier power in the generics market in France, 2009 29
Figure 17: Factors influencing the likelihood of new entrants in the generics market
in France, 2009 30
Figure 18: Factors influencing the threat of substitutes in the generics market in
France, 2009 32
Figure 19: Drivers of degree of rivalry in the generics market in France, 2009 33
Figure 20: France generics market value forecast: $ billion, 2009–14 34
Figure 21: France generics market volume forecast: volume penetration, 2009–14
36
Figure 22: France OTC pharmaceuticals market value: $ million, 2005–09 39
Figure 23: France OTC pharmaceuticals market segmentation I:% share, by value,
2009 40
Figure 24: France OTC pharmaceuticals Market Segmentation II: % share, by
value, 2009 41
Figure 25: France OTC pharmaceuticals market share: % share, by value, 2009 42
Figure 26: Forces driving competition in the OTC pharmaceuticals market in France,
2009 43
Figure 27: Drivers of buyer power in the OTC pharmaceuticals market in France,
2009 45
Figure 28: Drivers of supplier power in the OTC pharmaceuticals market in France,
2009 46
Figure 29: Factors influencing the likelihood of new entrants in the OTC
pharmaceuticals market in France, 2009 47
Figure 30: Factors influencing the threat of substitutes in the OTC pharmaceuticals
market in France, 2009 49
Figure 31: Drivers of degree of rivalry in the OTC pharmaceuticals market in
France, 2009 50
Figure 32: France OTC pharmaceuticals market distribution: % share, by value,
2009 51
Figure 33: France OTC pharmaceuticals market value forecast: $ million, 2009–14
53
Figure 34: France pharmaceuticals market value: $ billion, 2006–10(e) 56
Figure 35: France pharmaceuticals market segmentation I:% share, by value,
2010(e) 57
Figure 36: France pharmaceuticals Market Segmentation II: % share, by value,
2010(e) 58



PipelineReview.com is powered by La Merie Business Intelligence

La Merie S.L | C/Casp 33 B, 4º 2ª | E-08010 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 |
Email info@lamerie.com
| Internet www.lamerie.com


Online Store: www.pipelinereview.com

Reports



Figure 37: France pharmaceuticals market share: % share, by value, 2010(e) 59
Figure 38: Forces driving competition in the pharmaceuticals market in France,
2010 60
Figure 39: Drivers of buyer power in the pharmaceuticals market in France, 2010
62
Figure 40: Drivers of supplier power in the pharmaceuticals market in France, 2010
63
Figure 41: Factors influencing the likelihood of new entrants in the pharmaceuticals
market in France, 2010 65
Figure 42: Factors influencing the threat of substitutes in the pharmaceuticals
market in France, 2010 67
Figure 43: Drivers of degree of rivalry in the pharmaceuticals market in France,
2010 68
Figure 44: France pharmaceuticals market value forecast: $ billion, 2010–15 70